Renal manifestations in the metabolic syndrome

被引:126
作者
Locatelli, Francesco [1 ]
Pozzoni, Pietro [1 ]
Del Vecchio, Lucia [1 ]
机构
[1] A Manzoni Hosp, Dept Nephrol & Dialysis, I-23900 Lecce, Italy
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷 / 04期
关键词
D O I
10.1681/ASN.2005121332
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The metabolic syndrome, which is characterized by obesity, serum lipid profile alterations, hypertension, and fasting hyperglycemia, is very common in developed countries, and its prevalence is likely to increase. Chronic kidney disease (CKD) also has become a significant public health problem because it affects a considerable proportion of the adult population and is a major risk factor for cardiovascular disease and premature death. Although it is widely known that the metabolic syndrome is a major risk factor for the development of type 2 diabetes and cardiovascular disease, its precise relationship with the risk for renal impairment only recently has been clarified: Patients with the metabolic syndrome are at significantly higher risk for microalbuminuria and/or CKD, and the level of risk is related to the number of components of the syndrome itself. Although it is difficult to discriminate the detrimental renal effects of the metabolic syndrome from those of hypertension and impaired glucose metabolism, its other aspects (particularly obesity) may favor independently the development of renal abnormalities and may be considered new modifiable risk factors for CKD. These observations provide a rationale for intervention studies that aim to verify whether treating the many components of the metabolic syndrome can effectively prevent the development and progression of renal damage.
引用
收藏
页码:S81 / S85
页数:5
相关论文
共 38 条
[1]   The effects of weight loss on renal function in patients with severe obesity [J].
Chagnac, A ;
Weinstein, T ;
Herman, M ;
Hirsh, J ;
Gafter, U ;
Ori, Y .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (06) :1480-1486
[2]   Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data [J].
Chaturvedi, N .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (05) :370-379
[3]   The metabolic syndrome and chronic kidney disease in US adults [J].
Chen, J ;
Muntner, P ;
Hamm, LL ;
Jones, DW ;
Batuman, V ;
Fonseca, V ;
Whelton, PK ;
He, J .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (03) :167-174
[4]   Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000 [J].
Coresh, J ;
Byrd-Holt, D ;
Astor, BC ;
Briggs, JP ;
Eggers, PW ;
Lacher, DA ;
Hostetter, TH .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (01) :180-188
[5]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[6]   HYPERINSULINEMIA - THE KEY FEATURE OF A CARDIOVASCULAR AND METABOLIC SYNDROME [J].
FERRANNINI, E ;
HAFFNER, SM ;
MITCHELL, BD ;
STERN, MP .
DIABETOLOGIA, 1991, 34 (06) :416-422
[7]   Increasing prevalance of the metabolic syndrome among U.S adults [J].
Ford, ES ;
Giles, WH ;
Mokdad, AH .
DIABETES CARE, 2004, 27 (10) :2444-2449
[8]   Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey [J].
Ford, ES ;
Giles, WH ;
Dietz, WH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03) :356-359
[9]   Effect of lipid reduction on the progression of renal disease: A meta-analysis [J].
Fried, LF ;
Orchard, TJ ;
Kasiske, BL .
KIDNEY INTERNATIONAL, 2001, 59 (01) :260-269
[10]   Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].
Gaede, P ;
Vedel, P ;
Larsen, N ;
Jensen, GVH ;
Parving, H ;
Pedersen, O .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393